Bulletin
Investor Alert

Market Pulse Archives

June 16, 2021, 7:55 a.m. EDT

Regeneron says its COVID-19 antibody treatment cuts the risk of death among hospitalized patients

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Regeneron Pharmaceuticals Inc. (REGN)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN -1.46% gained 0.1% in premarket trading on Wednesday after the company said its COVID-19 antibody therapy cut the risk of death in patients who have been hospitalized by 20%. This is the first time clinical research has demonstrated that Regeneron's antibody treatment has improved survival for hospitalized patients. The study, which is being conducted in the U.K. in patients who have not yet developed antibodies, follows other research that showed the company's antibody treatment can improve recovery times among people with mild or moderate forms of the disease. Regeneron said it is planning to ask the Food and Drug Administration to expand the emergency-use authorization in the U.S. to include these types of patients. Regeneron's stock is up 9.2% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -0.54% has gained 13.0%.

/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 574.61
-8.52 -1.46%
Volume: 775,642
July 30, 2021 4:00p
P/E Ratio
16.26
Dividend Yield
N/A
Market Cap
$61.22 billion
Rev. per Employee
$931,393
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,395.26
-23.89 -0.54%
Volume: 2.25B
July 30, 2021 5:06p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.